Aberrant miR-29 is a predictive feature of severe phenotypes in pediatric Crohn’s disease
Shumway, A., Shanahan, M. T., Hollville, E., Chen, K., Beasley, C., Villanueva, J. W., Albert, S., Lian, G., Cure, M. R., Schaner, M., Zhu, L., Bantumilli, S., Deshmukh, M., Furey, T. S., Sheikh, S. Z., Sethupathy, P.
Impact of abiotic factors and husbandry on saprolegniosis in salmonid farms
Tedesco, P., Saraiva, M., Sandoval-Sierra, J. V., Alves, M. T., Galuppi, R., Dieguez-Uribeondo, J., van West, P., Cook, A., Posen, P., Oidtmann, B., Fioravanti, M.
S100A8/A9 drives the formation of procoagulant platelets through GPIbα
Colicchia, M., Schrottmaier, W. C., Perrella, G., Reyat, J. S., Begum, J., Slater, A., Price, J., Clark, J. C., Zhi, Z., Simpson, M. J., Bourne, J. H., Poulter, N. S., Khan, A. O., Nicolson, P. L., Pugh, M., Harrison, P., Iqbal, A. J., Rainger, G. E., Watson, S. P., Thomas, M. R., Mutch, N. J., Assinger, A., Rayes, J.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
Schlaich, M., Bellet, M., Weber, M. A., Danaietash, P., Bakris, G. L., Flack, J. M., Dreier, R. F., Sassi-Sayadi, M., Haskell, L. P., Narkiewicz, K., Wang, J., Reid, C., Schlaich, M., Katz, I., Ajani, A., Biswas, S., Esler, M., Elder, G., Roger, S., Colquhoun, D., Mooney, J., De Backer, T., Persu, A., Chaumont, M., Krzesinski, J., Vanabsche, T., Girard, G., Pliamm, L., Schiffrin, E., Merali, F., Dresser, G., Vallee, M., Jolly, S., Chow, S., Wang, J., Mu, J., Yu, J., Yuan, H., Feng, Y., Zhang, X., Xie, J., Lin, L., Soucek, M., Widimsky, J., Cifkova, R., Vaclavik, J., Ullrych, M., MacLeod, M., McLay, J., Calhoun, D., PRECISION investigators, Macleod, M.
In vitro characterisation of 6-methyl-3-(2-nitro-1-(thiophen- 2-yl)ethyl)-2-phenyl-1Hindole (ZCZ011) at the type 1 cannabinoid receptor: allosteric agonist or allosteric modulator?
Green, H. M., Finlay, D. B., Ross, R. A., Greig, I., Duffull, S. B., Glass, M.